More on DVAX

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (-28.6% Growth)
- Ratings (6.7 Score)
- Holders
- FDA

Financials

Income Statement
Balance Sheet
Cash Flow Statement

Upcoming Events

- Earnings (2/7/17 *Est.)
- PDUFA (12/15/2016)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

DVAX Cash Flow Statement

Click line-items for a historical chart and %
Operating activities
Net loss -90.7M
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization 1.57M
Amortization of intangible assets
(Gain)/Loss on disposal of assets
Non-cash interest associated with long-term note payable to Symphony Dynamo Holdings LLC
Fair value adjustment of the warrant and contingent liabilities to Symphony Dynamo Holdings LLC
Accretion and amortization of marketable securities 155K
Stock-based compensation expense 10.03M
Changes in operating assets and liabilities:
Accounts receivable
Prepaid expenses and other current assets
Restricted cash and other assets -99K
Accounts payable 704K
Accrued liabilities and other long term liabilities
Deferred revenues -2.65M
Net cash used in operating activities
Investing activities
Purchases of marketable securities -122.03M
Proceeds from maturities of marketable securities
Purchases of property and equipment, net -6.52M
Net cash provided (used) by investing activities
Financing activities
Proceeds from issuance of common stock, net of issuance costs 0
Proceeds from employee stock purchase plan 616K
Proceeds from exercise of stock options 131K
Proceeds from exercise of warrants
Net cash provided by financing activities
Effect of exchange rate on cash and cash equivalents 104K
Net increase (decrease) in cash and cash equivalents -21.79M
Cash and cash equivalents at beginning of period 44.81M
Cash and cash equivalents at end of period 23.02M
Supplemental disclosure of cash flow information
Disposal of fully depreciated assets 1.16M
Net change in unrealized gain on marketable securities